细胞癌中的表观遗传失调长非编码RNA基于多omics数据及其对向药物敏感性的影响
Jiawei Wang1, Pingnan Dou1,2, Yunwen Sun1,3
1Department of Urology, The Second People's Hospital of Wuhu, Wuhu, China.
Frontiers in genetics
|August 19, 2024
概括
这项研究确定了癌中长非编码RNA (lncRNAs) 的12个表观遗传异常. 八个lncRNAs作为清细胞细胞癌 (ccRCC) 的预后标志物,影响治疗策略.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 基因组学就是基因组学.
背景情况:
- 表观遗传修饰在癌症发展中至关重要.
- 长非编码RNAs (lncRNAs) 越来越多地被认为是它们在各种癌症中的作用.
- 了解癌中lncRNAs的表观遗传失调对于向治疗至关重要.
研究的目的:
- 为了确定与癌相关的 lncRNAs 中显著的表观遗传异常.
- 探索癌中这些表观遗传变化的预后价值.
- 调查潜在的治疗影响,包括针对性治疗和免疫治疗的反应.
主要方法:
- 利用了来自癌症基因组图谱 (TCGA),国际癌症基因组联盟 (ICGC) 和基因表达总汇 (GEO) 的公共数据.
- 分析了使用R软件在lncRNA促进器和增强器区域的基因素修饰 (H3K27ac,H3K4me1,H3K4me3) 和甲基化.
- 进行了预后分析,风险评分评估和生物丰富/免疫透分析.
主要成果:
- 在癌中确定了12种IncRNA基因的特异性表观遗传障碍.
- 发现了8种具有明显预测清细胞细胞癌 (ccRCC) 预后能力的lncRNAs.
- 发现高风险得分可能与对阿克西替尼和尼洛替尼的更好反应相关,并且在免疫疗法不响应者中升高.
结论:
- 这项研究增强了对癌中表观遗传失调的lncRNAs的理解.
- 鉴定到的 lncRNAs 具有作为ccRCC预后和个性化治疗策略的生物标志物的潜力.
- 对这些表观遗传变化的进一步调查可能为新的治疗干预措施铺平道路.
相关概念视频
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


